AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27339796 — intervention group
Group type: EXPERIMENTAL
Intervention: Newspapers and Magazines
Number of subjects: 82
Study 27339796 — intervention group
Group type: EXPERIMENTAL
Intervention: Peers with Diabetes
Number of subjects: 82
Study 24817084 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-laxative preparation
Number of subjects: 603
Study 24817084 — intervention group
Group type: EXPERIMENTAL
Intervention: CT colonography (CTC)
Number of subjects: 603
Study 24817084 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FS)
Number of subjects: 603
Study 24817084 — intervention group
Group type: COMPARATOR
Intervention: Optical colonoscopy (OC)
Number of subjects: 603
Study 22745235 — intervention group
Group type: EXPERIMENTAL
Intervention: HAM‐RS2 (40 g/d)
Number of subjects: 15
Study 22745235 — intervention group
Group type: EXPERIMENTAL
Intervention: HAM‐RS2
Number of subjects: 15
Study 22745235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 20354010 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung recruitment manoeuvre of 40 cm H(2)O for 15 s, followed by 10 cm H(2)O of PEEP and then 10 cm H(2)O of CPAP until extubation
Number of subjects: 44
Study 20354010 — intervention group
Group type: COMPARATOR
Intervention: No lung recruitment manoeuvre, <or=5 cm H(2)O PEEP, and no CPAP
Number of subjects: 44
Study 18478213 — intervention group
Group type: EXPERIMENTAL
Intervention: NGF (5 microg in 0.2 ml) injection into the masseter muscle
Number of subjects: 14
Study 18478213 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (0.9%, 0.2 ml) injection into the masseter muscle
Number of subjects: 14
Study 18478213 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate (1 M, 0.2 ml) injection after 24 h
Number of subjects: 14
Study 18478213 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate injection
Number of subjects: 14
Study 16127030 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 746
Study 12420567 — intervention group
Group type: EXPERIMENTAL
Intervention: TefGen‐GTR (guided tissue regeneration with a nonresorbable barrier)
Number of subjects: 10
Study 12420567 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement alone (control)
Number of subjects: 10
Study 10369259 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with ALOX5-pathway modifiers
Number of subjects: 0
Study 10369259 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 8835296 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with osteophytic calcifications (OC)
Number of subjects: 150
Study 8835296 — intervention group
Group type: COMPARATOR
Intervention: Normals (without OC)
Number of subjects: 150
Study 2203282 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg epinephrine (LE)
Number of subjects: 80
Study 2203282 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms fentanyl (LF)
Number of subjects: 80
Study 2203282 — intervention group
Group type: EXPERIMENTAL
Intervention: epinephrine and fentanyl (LFE)
Number of subjects: 80
Study 2203282 — intervention group
Group type: COMPARATOR
Intervention: 0.4 ml saline (L)
Number of subjects: 80
Study 7032304 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin ophthalmic solution
Number of subjects: 66
Study 7032304 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin sulfate ophthalmic solution
Number of subjects: 66
Study 31020002 — intervention group
Group type: EXPERIMENTAL
Intervention: Tui Na plus conventional rehabilitation
Number of subjects: 222
Study 31020002 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation only (control group)
Number of subjects: 222
Study 28603808 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Number of subjects: 103
Study 28603808 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 103
Study 25782685 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT + CRT
Number of subjects: 66
Study 25782685 — intervention group
Group type: COMPARATOR
Intervention: CRT
Number of subjects: 66
Study 23018820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (SOC enhancement intervention)
Number of subjects: 261
Study 23018820 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 261
Study 22852835 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Motivational Interviewing (GMI) and environmental modifications
Number of subjects: 0
Study 22852835 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental modifications
Number of subjects: 0
Study 22852835 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Motivational Interviewing (GMI)
Number of subjects: 0
Study 22852835 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study 19809809 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenugreek seed extract (588 mg)
Number of subjects: 12
Study 19809809 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenugreek seed extract (1176 mg)
Number of subjects: 12
Study 19809809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17578980 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral controlled-release oxycodone every 12 hours from the evening before surgery until the second postoperative morning.
Number of subjects: 40
Study 17578980 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 12 hours from the evening before surgery until the second postoperative morning.
Number of subjects: 40
Study 17578980 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral controlled-release oxycodone
Number of subjects: 40
Study 17578980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16353064 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (ephox-long, 50-100 mg o.d.)
Number of subjects: 30
Study 16353064 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (nitrosorbide, 10-20 mg t.i.d.)
Number of subjects: 30
Study 12239440 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan-depleting amino acid mixture (TD)
Number of subjects: 12
Study 12239440 — intervention group
Group type: COMPARATOR
Intervention: Placebo mixture
Number of subjects: 12
Study 10468697 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg b.d. during dosing
Number of subjects: 11
Study 10468697 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg b.d. before dosing
Number of subjects: 11
Study 10468697 — intervention group
Group type: COMPARATOR
Intervention: MRD dilution
Number of subjects: 11
Study 10468697 — intervention group
Group type: COMPARATOR
Intervention: HCl-KCl dilution
Number of subjects: 11
Study 7572016 — intervention group
Group type: COMPARATOR
Intervention: isoflurane
Number of subjects: 20
Study 7572016 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane plus nitrous oxide
Number of subjects: 20
Study 2079386 — intervention group
Group type: EXPERIMENTAL
Intervention: viloxazine (400 mg per os daily)
Number of subjects: 30
Study 2079386 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 6998538 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose heparin prophylaxis (5000 i.u. every 12 h for 5‐7 days) + graduated compression stockings
Number of subjects: 98
Study 6998538 — intervention group
Group type: COMPARATOR
Intervention: Control leg (no graduated compression stocking)
Number of subjects: 98
Study 31977859 — intervention group
Group type: EXPERIMENTAL
Intervention: Square dancing participation
Number of subjects: 1732
Study 31075612 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthy comfort eating during stress anticipation
Number of subjects: 150
Study 31075612 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthy comfort eating after the stressor
Number of subjects: 150
Study 31075612 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy comfort eating during stress anticipation
Number of subjects: 150
Study 31075612 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy comfort eating after the stressor
Number of subjects: 150
Study 31075612 — intervention group
Group type: COMPARATOR
Intervention: No food control
Number of subjects: 150
Study 28134558 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia care management
Number of subjects: 75
Study 28134558 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 75
Study 25283480 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose vitamin D3 (2000 IU/800 IU)
Number of subjects: 260
Study 25283480 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose vitamin D3 (1000 IU/400 IU)
Number of subjects: 260
Study 25283480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 23384334 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine pre-anesthesia evaluation
Number of subjects: 200
Study 23384334 — intervention group
Group type: COMPARATOR
Intervention: In-person pre-anesthesia evaluation
Number of subjects: 200
Study 22332431 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigational skills training (9 sessions)
Number of subjects: 0
Study 19573122 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (QW)
Number of subjects: 295
Study 19573122 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide twice daily (BID)
Number of subjects: 295
Study 19573122 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide QW (after switching from BID)
Number of subjects: 295
Study 19573122 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide QW
Number of subjects: 295
Study 19573122 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide BID
Number of subjects: 295
Study 17112529 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (n=20)
Number of subjects: 40
Study 17112529 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 40
Study 14963183 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital magnification (group A; n = 15)
Number of subjects: 30
Study 14963183 — intervention group
Group type: COMPARATOR
Intervention: Shorter field of view (group B; n = 15)
Number of subjects: 30
Study 11028574 — intervention group
Group type: COMPARATOR
Intervention: Traditional antenatal care
Number of subjects: 593
Study 11028574 — intervention group
Group type: COMPARATOR
Intervention: Flexible antenatal care
Number of subjects: 593
Study 11028574 — intervention group
Group type: EXPERIMENTAL
Intervention: Locus of control scale
Number of subjects: 593
Study 9183481 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous cycle ergometer programme
Number of subjects: 30
Study 9183481 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint running programme
Number of subjects: 30
Study 9183481 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 1994657 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise echocardiography
Number of subjects: 75
Study 1994657 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT
Number of subjects: 75
Study 1994657 — intervention group
Group type: COMPARATOR
Intervention: Exercise ECG
Number of subjects: 75
Study 6140220 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (10 mg i.v.)
Number of subjects: 0
Study 6140220 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.3 mg p.o.)
Number of subjects: 0
Study 6140220 — intervention group
Group type: COMPARATOR
Intervention: Resting plasma catecholamines (norepinephrine alone or total)
Number of subjects: 0
Study 31775839 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum ACE
Number of subjects: 99
Study 31775839 — intervention group
Group type: COMPARATOR
Intervention: Sham ACE
Number of subjects: 99
Study 31775839 — intervention group
Group type: COMPARATOR
Intervention: Waiting List (WL)
Number of subjects: 99
Study 30107819 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured, non-pharmacological care delivered by students of medicine, psychology and nursing, together with standard medical treatment
Number of subjects: 416
Study 30107819 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care alone
Number of subjects: 416
Study 30107819 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured evaluation of cognition, mood, anxiety and functional performance
Number of subjects: 416
Study 30107819 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured screening assessment for delirium using the Confusion Assessment Method
Number of subjects: 416
Study 26214142 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention program (group/home-based practices)
Number of subjects: 36
Study 26214142 — intervention group
Group type: EXPERIMENTAL
Intervention: Social cognitive theory (SCT) framework
Number of subjects: 36
Study 25644495 — intervention group
Group type: EXPERIMENTAL
Intervention: Septal body volume reduction (SBVR) with concurrent bilateral microdebrider-assisted SBVR during turbinate surgery
Number of subjects: 51
Study 25644495 — intervention group
Group type: COMPARATOR
Intervention: Conventional turbinoplasty only (ITR)
Number of subjects: 51
Study 22282887 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus insertion of a lumbar drain
Number of subjects: 210
Study 22282887 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 210
Study 20357366 — intervention group
Group type: EXPERIMENTAL
Intervention: PYY(3‐36) and oxyntomodulin coadministration
Number of subjects: 12
Study 20357366 — intervention group
Group type: COMPARATOR
Intervention: PYY(3‐36) alone
Number of subjects: 12
Study 20357366 — intervention group
Group type: COMPARATOR
Intervention: Oxyntomodulin alone
Number of subjects: 12
Study 20357366 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 12
Study 18065789 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial lock solution (ALS)
Number of subjects: 829
Study 18065789 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin lock
Number of subjects: 829
Study 16107989 — intervention group
Group type: EXPERIMENTAL
Intervention: DMAS device with monthly adherence counseling
Number of subjects: 64
Study 16107989 — intervention group
Group type: COMPARATOR
Intervention: Control group with only adherence counseling
Number of subjects: 64
Study 16107989 — intervention group
Group type: EXPERIMENTAL
Intervention: DMAS device for memory-impaired subjects
Number of subjects: 64
Study 16107989 — intervention group
Group type: COMPARATOR
Intervention: Control group for memory-impaired subjects
Number of subjects: 64
Study 16107989 — intervention group
Group type: EXPERIMENTAL
Intervention: DMAS device for memory-intact subjects
Number of subjects: 64
Study 16107989 — intervention group
Group type: COMPARATOR
Intervention: Control group for memory-intact subjects
Number of subjects: 64
Study 16107989 — intervention group
Group type: EXPERIMENTAL
Intervention: DMAS device at week 12
Number of subjects: 64
Study 16107989 — intervention group
Group type: COMPARATOR
Intervention: Control group at week 12
Number of subjects: 64
Study 16107989 — intervention group
Group type: EXPERIMENTAL
Intervention: DMAS device at week 24
Number of subjects: 64
Study 16107989 — intervention group
Group type: COMPARATOR
Intervention: Control group at week 24
Number of subjects: 64
Study 16107989 — intervention group
Group type: EXPERIMENTAL
Intervention: DMAS device and CD4(+) cell counts
Number of subjects: 64
Study 16107989 — intervention group
Group type: COMPARATOR
Intervention: Control group and CD4(+) cell counts
Number of subjects: 64
Study 12044304 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone and rifampin
Number of subjects: 41
Study 12044304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 10588408 — intervention group
Group type: EXPERIMENTAL
Intervention: MacArthur‐Maudsley Delusions Assessment Schedule
Number of subjects: 1136
Study 10588408 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia diagnosis
Number of subjects: 1136
Study 10588408 — intervention group
Group type: EXPERIMENTAL
Intervention: Grandiose and religious delusions
Number of subjects: 1136
Study 10588408 — intervention group
Group type: EXPERIMENTAL
Intervention: Persecutory delusions
Number of subjects: 1136
Study 10588408 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor analysis of dimensions
Number of subjects: 1136
Study 8701626 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol and GnRH‐analogon pretreatment
Number of subjects: 40
Study 1668828 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for early breast cancer
Number of subjects: 0
Study 1668828 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of surgery in the menstrual cycle
Number of subjects: 0
Study 1668828 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary dissection
Number of subjects: 0
Study 320671 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen, 1,800 mg/day
Number of subjects: 437
Study 320671 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 3,600 mg/day
Number of subjects: 437
Study 320671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 437
Study 31995406 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized antihypertensive treatment (triple therapy)
Number of subjects: 77
Study 31995406 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-SBP-day-SBP difference
Number of subjects: 77
Study 27882555 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day RBCs
Number of subjects: 8
Study 27882555 — intervention group
Group type: COMPARATOR
Intervention: 42-day RBCs
Number of subjects: 8
Study 25552575 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (target SBP <140 mm Hg within 1 hour, lower limit of 130 mm Hg for treatment cessation)
Number of subjects: 2839
Study 25552575 — intervention group
Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure lowering (target SBP <180 mm Hg)
Number of subjects: 2839
Study 25552575 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved SBP above 130 mm Hg
Number of subjects: 2839
Study 25552575 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved SBP below 130 mm Hg
Number of subjects: 2839
Study 23499474 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberate practice and one-on-one instruction for medical students
Number of subjects: 10
Study 23499474 — intervention group
Group type: COMPARATOR
Intervention: Nonsimulator-trained senior general surgery residents (N=11)
Number of subjects: 10
Study 21528598 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion
Number of subjects: 63
Study 21528598 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 mg orally after breakfast)
Number of subjects: 63
Study 20467616 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐ to 16‐mm‐long implants after lateral sinus lifting with 50% anorganic bovine (Bio‐Oss) and 50% autogenous bone
Number of subjects: 40
Study 20467616 — intervention group
Group type: COMPARATOR
Intervention: 8‐mm‐long implants after crestal sinus lifting with autogenous bone
Number of subjects: 40
Study 22872734 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant glycoprotein E vaccine (HZ/su; n = 45)
Number of subjects: 110
Study 22872734 — intervention group
Group type: COMPARATOR
Intervention: Live attenuated Oka strain VZV vaccine (OKA; n = 45)
Number of subjects: 110
Study 22872734 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HZ/su and OKA administered concomitantly (n = 45)
Number of subjects: 110
Study 22872734 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant glycoprotein E vaccine (HZ/su; n = 10) in young adults
Number of subjects: 110
Study 22872734 — intervention group
Group type: COMPARATOR
Intervention: Live attenuated Oka strain VZV vaccine (OKA; n = 10) in young adults
Number of subjects: 110
Study 16163369 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant administration followed by extubation to NCPAP (N=52)
Number of subjects: 105
Study 16163369 — intervention group
Group type: COMPARATOR
Intervention: NCPAP alone (Control group, N=53)
Number of subjects: 105
Study 16163369 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant administration
Number of subjects: 105
Study 12745512 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine inhaler (NI) plus nicotine patch (NP) (15 mg nicotine/16 h) for 6 weeks, then NI plus placebo patch (PP) for 6 weeks, then NI alone for 14 weeks.
Number of subjects: 400
Study 12745512 — intervention group
Group type: COMPARATOR
Intervention: Nicotine inhaler (NI) plus placebo patch (PP) for 12 weeks, then NI alone for 14 weeks.
Number of subjects: 400
Study 12745512 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 400
Study 10436278 — intervention group
Group type: EXPERIMENTAL
Intervention: Excised synovial membrane from patients with sinus tarsi syndrome
Number of subjects: 22
Study 10436278 — intervention group
Group type: COMPARATOR
Intervention: Excised synovial membrane from controls
Number of subjects: 22
Study 10436278 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological examination in 5 patients
Number of subjects: 22
Study 8829892 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg suppositories
Number of subjects: 325
Study 8829892 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg suppositories
Number of subjects: 325
Study 2796625 — intervention group
Group type: EXPERIMENTAL
Intervention: EXACON thermal therapy system model TT8200
Number of subjects: 20
Study 2796625 — intervention group
Group type: COMPARATOR
Intervention: Thermal blanket of aquamatic K‐thermia model PK‐600
Number of subjects: 20
Study 81723 — intervention group
Group type: EXPERIMENTAL
Intervention: Puncture skin tests with 1:20 w/v concentration of food extracts
Number of subjects: 76
Study 81723 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal skin tests
Number of subjects: 76
Study 81723 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind food challenge
Number of subjects: 76
Study 29271026 — intervention group
Group type: EXPERIMENTAL
Intervention: V-AC (vonoprazan 20 mg bid, amoxicillin 750 mg bid, and clarithromycin 200 or 400 mg bid)
Number of subjects: 147
Study 29271026 — intervention group
Group type: COMPARATOR
Intervention: PPI-AC (lansoprazole 30 mg, rabeprazole 10 mg, or esomeprazole 20 mg bid; amoxicillin 750 mg bid; and clarithromycin 200 or 400 mg bid)
Number of subjects: 147
Study 29271026 — intervention group
Group type: EXPERIMENTAL
Intervention: V-AC
Number of subjects: 147